[go: up one dir, main page]

PL2281032T3 - Komórki TR1 do leczenia stanu artretycznego - Google Patents

Komórki TR1 do leczenia stanu artretycznego

Info

Publication number
PL2281032T3
PL2281032T3 PL09737985T PL09737985T PL2281032T3 PL 2281032 T3 PL2281032 T3 PL 2281032T3 PL 09737985 T PL09737985 T PL 09737985T PL 09737985 T PL09737985 T PL 09737985T PL 2281032 T3 PL2281032 T3 PL 2281032T3
Authority
PL
Poland
Prior art keywords
arthritis
cells
treatment
Prior art date
Application number
PL09737985T
Other languages
English (en)
Inventor
Arnaud Foussat
Valérie Brun
Hélène Asnagli
Nathalie Belmonte
Christian Jorgensen
Original Assignee
Txcell
Université De Montpellier
Centre Hospitalier Regional Universitaire De Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Txcell, Université De Montpellier, Centre Hospitalier Regional Universitaire De Montpellier filed Critical Txcell
Publication of PL2281032T3 publication Critical patent/PL2281032T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL09737985T 2008-04-28 2009-04-08 Komórki TR1 do leczenia stanu artretycznego PL2281032T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4830908P 2008-04-28 2008-04-28
EP08305133A EP2113560A1 (en) 2008-04-28 2008-04-28 Compositions for treating an arthritic condition

Publications (1)

Publication Number Publication Date
PL2281032T3 true PL2281032T3 (pl) 2017-01-31

Family

ID=39535829

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09737985T PL2281032T3 (pl) 2008-04-28 2009-04-08 Komórki TR1 do leczenia stanu artretycznego

Country Status (18)

Country Link
US (2) US20110038844A1 (pl)
EP (3) EP2113560A1 (pl)
JP (2) JP6111014B2 (pl)
KR (2) KR20160093090A (pl)
CN (2) CN102076845A (pl)
AU (1) AU2009242299B2 (pl)
BR (1) BRPI0911580A2 (pl)
CA (1) CA2722816C (pl)
DK (1) DK2281032T3 (pl)
ES (1) ES2599305T3 (pl)
HR (1) HRP20161221T1 (pl)
HU (1) HUE034048T2 (pl)
LT (1) LT2281032T (pl)
PL (1) PL2281032T3 (pl)
PT (1) PT2281032T (pl)
RU (1) RU2563360C2 (pl)
SI (1) SI2281032T1 (pl)
WO (1) WO2009132941A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2378287A1 (en) * 2010-04-15 2011-10-19 TXCell New method for isolating Tr1 cells
US8709433B2 (en) * 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
WO2013105707A1 (ko) * 2012-01-13 2013-07-18 가톨릭대학교 산학협력단 시트룰린화된 단백질에 특이적인 단클론 항체 및 이를 생산하는 하이브리도마 세포주
US20170232084A1 (en) 2013-04-26 2017-08-17 Enzo Biochem Inc. Immune modulation for the treatment of age-related macular degeneration
US20140322188A1 (en) * 2013-04-26 2014-10-30 Enzo Biochem, Inc. Tolerizing treatments for autoimmune disease
EP3047275B1 (en) 2013-09-06 2020-11-18 Consejo Nacional De Investigaciones Cientificas Y Tecnicas Compositions and methods for increasing mesenchymal stromal cell migration to tumors
CN107456454A (zh) * 2016-06-06 2017-12-12 先声药业有限公司 一种预防或治疗炎性疾病的药物组合物
CN107670021B (zh) * 2016-08-02 2020-09-18 富比积生物科技股份有限公司 五胜肽kttks在治疗退化性关节炎中的用途
CN107670020B (zh) * 2016-08-02 2020-09-18 富比积生物科技股份有限公司 四胜肽gekg在治疗退化性关节炎中的用途
CA3232037A1 (en) * 2021-09-21 2023-03-30 Monash University Methods of treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463101B2 (en) * 1989-03-21 2003-03-19 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
JP3712260B2 (ja) * 1992-02-28 2005-11-02 オートイミューン インク 自己免疫疾患のバイスタンダー抑制
US6746670B2 (en) 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
FR2856700B1 (fr) * 2003-06-24 2007-06-08 Txcell Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
WO2006018674A1 (en) * 2004-08-11 2006-02-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tr1 cells for use in atherosclerosis
EP1712615A1 (en) 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
DK1739166T3 (da) 2005-07-01 2011-10-10 Txcell S A Fremstilling af fødevare- eller autoantigen-specifikke Tr1-celler fra en leukocyt- eller PBMC-population

Also Published As

Publication number Publication date
ES2599305T3 (es) 2017-02-01
HRP20161221T1 (hr) 2017-01-13
JP2015007079A (ja) 2015-01-15
SI2281032T1 (sl) 2017-01-31
US20180250372A1 (en) 2018-09-06
EP3130666A1 (en) 2017-02-15
AU2009242299A1 (en) 2009-11-05
JP2011518797A (ja) 2011-06-30
EP2281032A1 (en) 2011-02-09
CN102076845A (zh) 2011-05-25
CA2722816C (en) 2018-01-09
JP6111014B2 (ja) 2017-04-05
PT2281032T (pt) 2016-11-11
DK2281032T3 (en) 2016-10-10
HUE034048T2 (en) 2018-01-29
KR20110017373A (ko) 2011-02-21
KR20160093090A (ko) 2016-08-05
LT2281032T (lt) 2016-11-25
KR101747902B1 (ko) 2017-06-16
US20110038844A1 (en) 2011-02-17
BRPI0911580A2 (pt) 2017-05-23
RU2563360C2 (ru) 2015-09-20
AU2009242299B2 (en) 2015-05-14
EP2281032B1 (en) 2016-08-03
CN108159407A (zh) 2018-06-15
EP2113560A1 (en) 2009-11-04
CA2722816A1 (en) 2009-11-05
WO2009132941A1 (en) 2009-11-05
RU2010148464A (ru) 2012-06-10

Similar Documents

Publication Publication Date Title
PL2281032T3 (pl) Komórki TR1 do leczenia stanu artretycznego
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
EP2339910A4 (en) GLASSHOUSE
BRPI0823297A2 (pt) Garrafa
BRPI0821652A2 (pt) tratamento de biocombustíveis
DK2173831T3 (da) Brøndbehandling
LT2313364T (lt) Simetrinio dimetilarginino nustatymo būdai
FR2944062B1 (fr) Injecteur d'ergols
IT1393443B1 (it) Stiratoio bitesta
FI20105881L (fi) Hydrosykloni
DK2346661T3 (da) Dannelsesfremgangsmåder
DE502007002429D1 (de) Endreaktor
FI20085583L (fi) Ratkaisu meesan käsittelemiseksi
EP2169142A4 (en) METHOD FOR MANUFACTURING FLOOR
FR2937940B1 (fr) Automotrice de transport de voyageurs
EP2300594A4 (en) ELECTROBIOCHEMICAL REACTOR
BRPI1013017A2 (pt) "17beta-alquil-17alfa-óxi-estratrienos"
FI20070190L (fi) Bioreaktori
EP2493665A4 (en) MULTISELECTIVE MICROMANIPULATOR
TH91873B (th) ขวด
IT1398148B1 (it) "auto-negozio"
UA19919S (uk) Цеглина пряма
FI7975U1 (fi) Ravinne
FI20085724A0 (fi) Soluviljely
FIU20080033U0 (fi) Pienpuhdistamo